Japanese study monitors safety of samsca for SIADH patients
NCT ID NCT04790175
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks the safety of the drug Samsca (tolvaptan) in 300 Japanese patients with low sodium levels caused by SIADH. Researchers will record any side effects or special situations that occur during routine use. The goal is to confirm the drug's safety in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tolvaptan (Samsca)
- What this could lead to
- If successful, this study will confirm that Samsca is safe for treating low sodium in SIADH patients in Japan, supporting its continued use.
- What could go wrong
- This is an observational safety study, not a test of how well the drug works. It may not lead to new treatments or change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIDIURETIC HORMONE, INAPPROPRIATE SECRETION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pharmacovigilance Department
Osaka, Osaka, 540-0021, Japan